LQDA (Liquidia) Valuation Rank


LQDA Liquidia Corp LQDA
67 GF Score
Price $75.12
GF Value $218.97
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Liquidia Valuation Rank Related Terms

LQDA
67GF Score
Liquidia Corp LQDA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $75.12 is trading 65.7% below its estimated GF Value™ of $218.97. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Valuation Rank:
  • GF Value™: $218.97 vs. price of $75.12 (65.7% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score

Get the complete analysis for LQDA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$75.12
Price
$218.97
GF Value